Table 5 ADMET molecular descriptors of compounds designed as leishmaniasis inhibitors.
From: Screening of the antileishmanial and antiplasmodial potential of synthetic 2-arylquinoline analogs
Compound | MW (g mol−1) | MR | LogP | HBA | HBD | TPSA (Å2) | LR | GR | VR | PR | Synth. Acce |
|---|---|---|---|---|---|---|---|---|---|---|---|
4a | 289.33 | 88.61 | 3.88 | 3 | 0 | 39.19 | 0 | 0 | 0 | 0 | 2.53 |
4b | 305.33 | 90.64 | 3.51 | 4 | 1 | 59.42 | 0 | 0 | 0 | 0 | 2.64 |
4c | 319.35 | 95.1 | 3.84 | 4 | 0 | 48.42 | 0 | 0 | 0 | 0 | 2.78 |
4d | 335.35 | 97.13 | 3.48 | 5 | 1 | 68.65 | 0 | 0 | 0 | 0 | 2.88 |
4e | 368.22 | 96.31 | 4.46 | 3 | 0 | 39.19 | 0 | 0 | 0 | 0 | 2.68 |
4f. | 333.38 | 99.91 | 4.16 | 4 | 0 | 48.42 | 0 | 0 | 0 | 0 | 2.66 |
